Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - VirtualScopics, Inc. | v313369_8k.htm |
EXHIBIT 99.1
500 Linden Oaks
Rochester, New York 14625
VirtualScopics Reports 1st Quarter 2012 Results
Earnings call scheduled for 11am ET today
ROCHESTER, NY – May 15, 2012 – VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging, today reported revenues for the first quarter of 2012 reached $3,702,159 compared to revenues of $3,658,977 in the first quarter of 2011. Gross profit for the quarter ended March 31, 2012 was $1,410,914 compared to $1,599,740 during the first quarter of 2011. Earnings before interest, taxes, depreciation and amortization, and excluding stock compensation expense and the unrealized loss on change in fair value of the derivative liabilities (“Adjusted EBITDA”) was $82,106 for the quarter ended March 31, 2012 compared to $392,942 for the quarter ended March 31, 2011. Net loss for the first quarter of 2012 was $613,544 compared to $200,381 in the first quarter of 2011.
“The first quarter of 2012 was one of the most active quarters in the company’s history in terms of image processing,” said Jeff Markin, president and chief executive officer of VirtualScopics. “We received a record level of images from study sites and our core lab outpaced any previous quarter. The slowdown in revenue growth and our product mix, however, resulted in lower gross margins than we’ve reported in prior quarters.” He added, “This underscores the importance of our focus on sales initiatives. Specifically of note, our business development team received a robust number of requests for proposals (RFPs) during the first quarter. Additionally, we are pleased to announce that RFP activity from our PPD alliance resulted in a more than doubling of requests when compared to the first quarter of 2011. This activity directly relates to the expansion of our strategic alliance with PPD announced earlier in the quarter.” He concluded, “We are encouraged by the level of activity we are seeing in the market and we are diligently working towards achievement of our 2012 goals.”
“With the support of an important strategic investment this year, we continue to make progress in the further development of our personalized medicine software applications,” stated Molly Henderson, chief business and financial officer of VirtualScopics. She added, “The proceeds of this recent financing will enable us to develop our quantitative imaging solutions for the broader medical community which we believe will enable improved patient care.” She concluded, “With this investment and our strong cash position, we are well-poised to take advantage of opportunities that we believe will be an integral part of the future success of the company.”
Jeff Markin and Molly Henderson will provide a business and first quarter 2012 financial update during the conference call today at 11:00 a.m. ET. Interested participants should call 877.407.8035 when calling within the United States or +1 201 689 8035 when calling internationally. This call can also be accessed at www.virtualscopics.com and will be available for 30 days after the call.
| -1- |
The Company provides Adjusted EBITDA as a supplemental measure to GAAP regarding the Company's operational performance. The Company defines Adjusted EBITDA as earnings less interest, taxes (if any), depreciation and amortization and further adjusted to exclude stock compensation expense and the unrealized loss on the change in fair value of derivative liabilities (mark to market adjustment for warrants). This financial measure excludes the impact of certain items and, therefore, has not been calculated in accordance with GAAP. The Company’s method of calculating Adjusted EBITDA, however, may differ from methods used by other companies, and, as a result, Adjusted EBITDA measures disclosed herein may not be comparable to other similarly titled measures used by other companies. The Company continues to provide information in accordance with GAAP. However, with the adoption of ASC 815-40 and the non-cash variable nature of stock compensation expense and their very substantial impact on the overall reported net income/loss, the Company believes it is also helpful for investors to receive additional information relating more specifically to the Company's operating results. Accordingly, the Company has presented Adjusted EBITDA which excludes the non-cash effects of ASC 815-40 and ASC 718 on its financial results. Management uses Adjusted EBITDA (a) to evaluate the Company's financial performance, (b) to set internal spending budgets, and (c) to measure operational profitability. In addition, investors have requested these non-GAAP financial measures as a means of providing consistent and comparable information with past reports of financial results. Pursuant to the requirements of Regulation G, the Company has provided a reconciliation of Adjusted EBITDA to the most directly comparable GAAP financial measure, net (loss)/income.
About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of quantitative imaging solutions to accelerate drug and medical device development in addition to improving patient care. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics’ industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.
####
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company’s investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words “believes,” “could,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “projects,” “seeks,” or similar expressions. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission (the “SEC”), and in any subsequent reports filed with the SEC, all of which are available at the SEC’s website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed. Other risks include the company’s dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.
-Financial tables to follow-
| -2- |
| CONTACTS: | Investor Relations: | Company Contact: |
| Tim Ryan | Molly Henderson | |
| The Shoreham Group | Chief Business and Financial Officer, Sr. Vice President | |
| 80 Eighth Ave, Ste 1107 | 500 Linden Oaks | |
| New York, NY 10011 | Rochester, New York 14625 | |
| +1 212 242 7777 Direct | +1 585 249.6231 | |
| tryan@shorehamgroupllc.com | ||
| -3- |
VirtualScopics, Inc. and Subsidiary
Condensed Consolidated Statements of Operations
(unaudited)
| For the Three Months Ended March 31, | ||||||||
| 2012 | 2011 | |||||||
| Revenues | $ | 3,293,659 | $ | 3,349,610 | ||||
| Reimbursement revenues | 408,500 | 309,367 | ||||||
| Total revenues | 3,702,159 | 3,658,977 | ||||||
| Cost of revenues | 1,882,745 | 1,749,870 | ||||||
| Cost of reimbursement revenues | 408,500 | 309,367 | ||||||
| Total cost of services | 2,291,245 | 2,059,237 | ||||||
| Gross profit | 1,410,914 | 1,599,740 | ||||||
| Operating expenses | ||||||||
| Research and development | 356,326 | 314,257 | ||||||
| Sales and marketing | 331,072 | 302,095 | ||||||
| General and administrative | 654,741 | 600,213 | ||||||
| Stock-based compensation expense | 175,936 | 234,205 | ||||||
| Depreciation and amortization | 111,619 | 137,224 | ||||||
| Total operating expenses | 1,629,694 | 1,587,994 | ||||||
| Operating (loss) income | (218,780 | ) | 11,746 | |||||
| Other income (expense) | ||||||||
| Interest income | 416 | 1,227 | ||||||
| Other expense | (268 | ) | (1,220 | ) | ||||
| Unrealized loss on change in fair value of derivative liabilities | (394,912 | ) | (212,134 | ) | ||||
| Total other expense | (394,764 | ) | (212,127 | ) | ||||
| Net loss | (613,544 | ) | (200,381 | ) | ||||
| Series B preferred stock cash dividend | 12,000 | 12,989 | ||||||
| Net loss attributable to common stockholders | $ | (625,544 | ) | $ | (213,370 | ) | ||
| Basic and diluted net loss per common share | $ | (0.02 | ) | $ | (0.01 | ) | ||
| Weighted average number of common shares outstanding basic and diluted | 29,370,687 | 28,038,723 | ||||||
| * | Cost of revenues includes non-cash stock-based compensation expense of $13,331 and $9,767 for the three months ended March 31, 2012 and 2011, respectively. |
| -4- |
VirtualScopics, Inc. and Subsidiary
Condensed Consolidated Balance Sheets
| March 31, | December 31, | |||||||
| 2012 | 2011 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash | $ | 5,290,341 | $ | 5,737,009 | ||||
| Accounts receivable, net | 3,018,148 | 2,435,496 | ||||||
| Prepaid expenses and other current assets | 463,238 | 361,376 | ||||||
| Total current assets | 8,771,727 | 8,533,881 | ||||||
| Patents, net | 1,549,637 | 1,582,938 | ||||||
| Property and equipment, net | 459,468 | 514,230 | ||||||
| Other assets | 21,712 | 27,140 | ||||||
| Total assets | $ | 10,802,544 | $ | 10,658,189 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 1,014,757 | $ | 843,275 | ||||
| Accrued payroll | 421,923 | 759,470 | ||||||
| Unearned revenue | 781,396 | 421,486 | ||||||
| Derivative liabilities | 551,508 | 156,596 | ||||||
| Total current liabilities | 2,769,584 | 2,180,827 | ||||||
| Commitments and Contingencies | - | - | ||||||
| Stockholders' Equity | ||||||||
| Convertible preferred stock, $0.001 par value; 15,000,000 shares authorized; | ||||||||
| Series A 8,400 shares authorized; issued and outstanding, 2,190 at March 31, 2012 and December 31, 2011; liquidation preference $1,000 per share | 2 | 2 | ||||||
| Series B 6,000 shares authorized; issued and outstanding, 600 at March 31, 2012 and December 31, 2011; liquidation preference $1,000 per share | 1 | 1 | ||||||
| Common Stock, $0.001 par value; 85,000,000 shares authorized; issued and outstanding, 29,370,687 shares at March 31, 2012 and December 31, 2011 | 29,371 | 29,371 | ||||||
| Additional paid-in capital | 18,052,078 | 17,882,936 | ||||||
| Accumulated deficit | (10,048,492 | ) | (9,434,948 | ) | ||||
| Total stockholders' equity | 8,032,960 | 8,477,362 | ||||||
| Total liabilities and stockholders' equity | $ | 10,802,544 | $ | 10,658,189 | ||||
| -5- |
| Three Months Ended | Three Months Ended | |||||||
| Adjusted EBITDA (non-GAAP measurement): | March 31, 2012 | March 31, 2011 | ||||||
| (unaudited) | (unaudited) | |||||||
| Net loss | $ | (613,544 | ) | $ | (200,381 | ) | ||
| Interest income and other expenses | (148 | ) | (7 | ) | ||||
| Depreciation and amortization | 111,619 | 137,224 | ||||||
| Stock-based compensation expense | 189,267 | 243,972 | ||||||
| Unrealized loss on change in fair value of derivative liabilities | 394,912 | 212,134 | ||||||
| Adjusted EBITDA | $ | 82,106 | $ | 392,942 | ||||
| Basic and diluted Adjusted EBITDA per common share, non-GAAP | $ | 0.00 | $ | 0.01 | ||||
| -6- |